Breaking News

FUJIFILM Irvine Scientific Expands BalanCD CHO Media Platform for Bioprocessing

Adds media to support DG44 cell lines and perfusion culture platforms for the commercialization of mAbs, recombinant proteins and other biotherapeutics.

FUJIFILM Irvine Scientific, Inc., a manufacturer of cell culture solutions for life sciences, is expanding its BalanCD CHO Media Platform portfolio with the addition of two new, chemically defined growth media- BalanCD CHO Perfusion and BalanCD CHO DG44.

The BalanCD CHO media portfolio is designed to ensure maximized growth, viability, and productivity of Chinese Hamster Ovary (CHO) cell lines via a scalable platform for reliable production and seamless workflow through all stages of development and manufacture, from small-scale shake flasks to large bioreactors. These new additions extend the platform with specific media designed to support DG44 cell lines and perfusion culture platforms for the commercialization of monoclonal antibodies, recombinant proteins, biosimilars, and other biomolecule-based biotherapeutics.

Erik Vaessen, chief business officer, FUJIFILM Irvine Scientific, said: “With CHO cells being such a pivotal part of many biotherapeutic development and manufacture pipelines, FUJIFILM Irvine Scientific designed the BalanCD CHO platform to deliver consistent, high-quality growth of CHO cells and production of biomolecules to accelerate the development and manufacture of life-saving therapies for patients around the world and achieve more cost-efficiencies within biotherapeutic manufacturing.”

BalanCD CHO Perfusion medium is a chemically defined, animal component-free medium optimized to deliver robust cell growth and productivity in steady-state, perfusion CHO culture. The medium is verified to meet industry performance standards for perfusion culture conditions including volumetric productivity (VP); cell specific perfusion rates (CSPR); and vessel volumes per day (VVD). BalanCD CHO Perfusion is a complete and ready-to-use medium that is adaptable and scalable for a variety of perfusion culture platforms, including perfusion mimic and perfusion-capable bioreactors.

Designed for high cell density conditions and to deliver high titers, BalanCD CHO DG44 medium is specifically developed for optimal growth and productivity of CHO DG44 cell lines. Chemically defined, animal component-free, BalanCD CHO DG44 supports both batch and fed-batch cultures and is compatible with a wide range of culture platforms and transfection reagents.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters